High expression of folate receptor alpha in lung cancer correlates with adenocarcinoma histology and mutation

Journal of Thoracic Oncology

Volumn 7, Issue 5, 2012, Pages 833-840

  Nunez, Maria Ines ^a   Behrens, Carmen ^a   Woods, Denise M ^a   Lin, Heather ^a   Suraokar, Milind ^a   Kadara, Humam ^a   Hofstetter, Wayne ^a   Kalhor, Neda ^a   Lee, J Jack ^a   Franklin, Wilbur ^b   Stewart, David J ^a   Wistuba, Ignacio I ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Epidermal growth factor receptor; Folate receptor alpha; Membrane transporter; Non small cell lung carcinoma; Reduced folate carrier 1

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; FOLATE RECEPTOR 1; MESSENGER RNA; PROTEIN P53; REDUCED FOLATE CARRIER; THYMIDYLATE SYNTHASE;

ADULT; AGED; CYTOPLASM; FEMALE; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; ONCOGENE K RAS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SMOKING; TISSUE MICROARRAY;

EID: 84861325993     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31824de09c     Document Type: Article

References (40)

1. Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med 2008;359:1367-1380.
2. Travis WD, Brambilla E, Muller-Hermelink HK,. et al. Tumours of the lung. In Travis WD, Brambilla E, Muller-Hermelink HK,. et al., (Eds), Pathology and Genetics: Tumours of the Lung, Pleura, Thymus and Heart. Lyon: International Agency for Research on Cancer (IARC), 2004. Pp. 9-124.
3. Pfister DG, Johnson DH, Azzoli CG,. et al.; American Society of Clinical Oncology. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 2004;22:330-353.
4. Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J; International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004;350:351-360.
5. Huang Y. Pharmacogenetics/genomics of membrane transporters in cancer chemotherapy. Cancer Metastasis Rev 2007;26:183-201.
6. Kelemen LE. The role of folate receptor alpha in cancer development, progression and treatment: cause, consequence or innocent bystander? Int J Cancer 2006;119:243-250.
7. Matherly LH, Hou Z, Deng Y. Human reduced folate carrier: translation of basic biology to cancer etiology and therapy. Cancer Metastasis Rev 2007;26:111-128.
8. Weitman SD, Weinberg AG, Coney LR, Zurawski VR, Jennings DS, Kamen BA. Cellular localization of the folate receptor: potential role in drug toxicity and folate homeostasis. Cancer Res 1992;52:6708-6711.
9. Hartmann LC, Keeney GL, Lingle WL,. et al. Folate receptor overexpression is associated with poor outcome in breast cancer. Int J Cancer 2007;121:938-942.
10. Bueno R, Appasani K, Mercer H, Lester S, Sugarbaker D. The alpha folate receptor is highly activated in malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2001;121:225-233.
11. Iwakiri S, Sonobe M, Nagai S, Hirata T, Wada H, Miyahara R. Expression status of folate receptor alpha is significantly correlated with prognosis in non-small-cell lung cancers. Ann Surg Oncol 2008;15:889-899.
12. Jin M, Kawakami K, Fukui Y,. et al. Different histological types of non-small cell lung cancer have distinct folate and DNA methylation levels. Cancer Sci 2009.
13. Shia J, Klimstra DS, Nitzkorski JR,. et al. Immunohistochemical expression of folate receptor alpha in colorectal carcinoma: patterns and biological significance. Hum Pathol 2008;39:498-505.
14. Scagliotti GV, Ceppi P, Capelletto E, Novello S. Updated clinical information on multitargeted antifolates in lung cancer. Clin Lung Cancer 2009;10 Suppl 1:S35-S40.
15. Taylor EC, Kuhnt D, Shih C,. et al. A dideazatetrahydrofolate analogue lacking a chiral center at C-6, N-[4-[2-(2-amino-3,4-dihydro-4-oxo-7H-pyrrolo[2, 3-d]pyrimidin-5- yl)ethyl]benzoyl]-L-glutamic acid, is an inhibitor of thymidylate synthase. J Med Chem 1992;35:4450-4454.
16. Schultz RM, Patel VF, Worzalla JF, Shih C. Role of thymidylate synthase in the antitumor activity of the multitargeted antifolate, LY231514. Anticancer Res 1999;19(1A):437-443.
17. Shih C, Habeck LL, Mendelsohn LG, Chen VJ, Schultz RM. Multiple folate enzyme inhibition: mechanism of a novel pyrrolopyrimidine-based antifolate LY231514 (MTA). Adv Enzyme Regul 1998;38:135-152.
18. Ebel W, Routhier EL, Foley B,. et al. Preclinical evaluation of MORAb-003, a humanized monoclonal antibody antagonizing folate receptor-alpha. Cancer Immun 2007;7:6.
19. Konner JA, Bell-McGuinn KM, Sabbatini P,. et al. Farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer: a phase I study. Clin Cancer Res 2010;16:5288-5295.
20. Spannuth WA, Sood AK, Coleman RL. Farletuzumab in epithelial ovarian carcinoma. Expert Opin Biol Ther 2010;10:431-437.
21. Shigematsu H, Lin L, Takahashi T,. et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005;97:339-346.
22. Tang X, Shigematsu H, Bekele BN,. et al. EGFR tyrosine kinase domain mutations are detected in histologically normal respiratory epithelium in lung cancer patients. Cancer Res 2005;65:7568-7572.
23. Rhodes DR, Yu J, Shanker K,. et al. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 2004;6:1-6.
24. Tomida S, Koshikawa K, Yatabe Y,. et al. Gene expression-based, individualized outcome prediction for surgically treated lung cancer patients. Oncogene 2004;23:5360-5370.
25. Bild AH, Yao G, Chang JT,. et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 2006;439:353-357.
26. Kim J. Prediction of recurrence-free survival in postoperative NSCLC patients-a useful prospective clinical practice. Available at http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE8894. Accessed August 29, 2007
27. Chen HY, Yu SL, Chen CH,. et al. A five-gene signature and clinical outcome in non-small-cell lung cancer. N Engl J Med 2007;356: 11-20.
28. Chitale D, Gong Y, Taylor BS,. et al. An integrated genomic analysis of lung cancer reveals loss of DUSP4 in EGFR-mutant tumors. Oncogene 2009;28:2773-2783.
29. Simon R, Lam A, Li MC, Ngan M, Menenzes S, Zhao Y. Analysis of gene expression data using BRB-ArrayTools. Cancer Inform 2007;3:11-17.
30. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP. Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res 2003;31:e15.
31. Sadlish H, Williams FM, Flintoff WF. Cytoplasmic domains of the reduced folate carrier are essential for trafficking, but not function. Biochem J 2002;364(Pt 3):777-786.
32. Scagliotti GV, Parikh P, von Pawel J,. et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543-3551.
33. Sun S, Schiller JH, Gazdar AF. Lung cancer in never smokers-a different disease. Nat Rev Cancer 2007;7:778-790.
34. Eberhard DA, Johnson BE, Amler LC,. et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005;23:5900-5909.
35. Adjei AA. Pemetrexed (ALIMTA), a novel multitargeted antineoplastic agent. Clin Cancer Res 2004;10(12 Pt 2):4276s-4280s.
36. Ceppi P, Volante M, Saviozzi S,. et al. Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. Cancer 2006;107:1589-1596.
37. Zheng Z, Li X, Schell MJ,. et al. Thymidylate synthase in situ protein expression and survival in stage I nonsmall-cell lung cancer. Cancer 2008;112:2765-2773.
38. Hanauske AR, Eismann U, Oberschmidt O,. et al. In vitro chemosensitivity of freshly explanted tumor cells to pemetrexed is correlated with target gene expression. Invest New Drugs 2007;25:417-423.
39. Sun JM, Han J, Ahn JS, Park K, Ahn MJ. Significance of thymidylate synthase and thyroid transcription factor 1 expression in patients with nonsquamous non-small cell lung cancer treated with pemetrexed-based chemotherapy. J Thorac Oncol 2011;6:1392-1399.
40. Liu J, Schmitz JC, Lin X,. et al. Thymidylate synthase as a translational regulator of cellular gene expression. Biochim Biophys Acta 2002;1587: 174-182.